We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-9.09%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
-$3.15B
Cap. Flow
+$225M
Cap. Flow %
1.29%
Top 10 Hldgs %
85.01%
Holding
121
New
2
Increased
15
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
KOD icon
Kodiak Sciences
KOD
+$48.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.2M
4
TSVT
2seventy bio
TSVT
+$20.9M
5
REPL icon
Replimune Group
REPL
+$19.2M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$20.1M
2
LEGN icon
Legend Biotech
LEGN
+$19M
3
OPT
Opthea Limited American Depositary Shares
OPT
+$3.19M
4
ALBO
Albireo Pharma Inc
ALBO
+$2.43M
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$1.55M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMTX
51
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$18.8M 0.11%
2,024,876
– –
OTIC
52
DELISTED
Otonomy, Inc.
OTIC
$18.8M 0.11%
7,844,692
– –
OPT
53
DELISTED
Opthea Limited American Depositary Shares
OPT
$18.5M 0.11%
2,696,191
-500,000
-16% -$3.19M
CRNX icon
54
Crinetics Pharmaceuticals
CRNX
$8.88B
$18.2M 0.1%
827,480
– –
TCDA
55
DELISTED
Tricida, Inc. Common Stock
TCDA
$14.2M 0.08%
1,731,714
+446,700
+35% +$4.04M
RLMD icon
56
Relmada Therapeutics
RLMD
$539M
$13.4M 0.08%
495,113
– –
FLGT icon
57
Fulgent Genetics
FLGT
$558M
$12.6M 0.07%
201,444
– –
BLUE
58
DELISTED
bluebird bio
BLUE
$12.1M 0.07%
124,986
– –
DICE
59
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$11.3M 0.06%
588,235
– –
BCEL
60
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$11.2M 0.06%
3,532,760
– –
ZYME icon
61
Zymeworks
ZYME
$1.61B
$11.2M 0.06%
1,708,472
– –
LONA
62
LeonaBio Inc
LONA
$66.4M
$10.9M 0.06%
80,637
– –
TLIS
63
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$10.8M 0.06%
508,322
– –
ANAB icon
64
AnaptysBio
ANAB
$1.53B
$10.6M 0.06%
427,179
– –
CNTA
65
DELISTED
Centessa Pharmaceuticals
CNTA
$10.1M 0.06%
1,127,273
– –
SRPT icon
66
Sarepta Therapeutics
SRPT
$1.64B
$9.64M 0.06%
123,456
– –
KRTX
67
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.87M 0.05%
69,966
– –
SYRE icon
68
Spyre Therapeutics
SYRE
$8.25B
$7.84M 0.05%
136,404
– –
VERA icon
69
Vera Therapeutics
VERA
$2.31B
$7.83M 0.05%
+333,333
New +$7.17M
ACHL
70
DELISTED
Achilles Therapeutics
ACHL
$7.62M 0.04%
2,591,366
– –
SRZN icon
71
Surrozen
SRZN
$217M
$7.53M 0.04%
166,667
– –
RETA
72
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$7.34M 0.04%
223,976
– –
NGNE icon
73
Neurogene
NGNE
$648M
$7.18M 0.04%
191,087
– –
KYNB
74
Kyntra Bio
KYNB
$28.1M
$6.99M 0.04%
23,270
+64
+0.3% +$22.3K
BMEA icon
75
Biomea Fusion
BMEA
$88.9M
$6.92M 0.04%
1,551,445
+1,026,828
+196% +$6.66M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Baker Bros. Advisors held 121 positions worth $17.4B, down 15% from $20.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 4.1%. Baker Bros. Advisors opened 2 new positions and exited 3, leaving the 121-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2022 buy was Vera Therapeutics: 333,333 shares worth $7.83M.
  • Baker Bros. Advisors added most to Incyte in Q1 2022, an estimated $184M increase.
  • Baker Bros. Advisors's biggest Q1 2022 reduction was ChemoCentryx, Inc., cutting an estimated $20.1M.
  • Baker Bros. Advisors fully exited Albireo Pharma Inc in Q1 2022, selling an estimated $2.43M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $17.4B portfolio in Q1 2022.
  • Baker Bros. Advisors opened 2 new positions and closed 3 in Q1 2022.
  • Baker Bros. Advisors's portfolio value fell 15% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q1 2022, filed 16 May 2022.